Holen Sie sich die Stockscreener-App
0.7037
1.14%
-0.0081
Handel nachbörslich:
.70
-0.0037
-0.53%
Schlusskurs vom Vortag:
$0.7118
Offen:
$0.7059
24-Stunden-Volumen:
60,805
Relative Volume:
0.15
Marktkapitalisierung:
$4.42M
Einnahmen:
$5.66M
Nettoeinkommen (Verlust:
$-15.88M
KGV:
-0.0622
EPS:
-11.3134
Netto-Cashflow:
$-10.93M
1W Leistung:
-8.21%
1M Leistung:
-15.40%
6M Leistung:
-48.64%
1J Leistung:
-92.93%
1-Tages-Spanne:
$0.6901
$0.7171
1-Wochen-Bereich:
$0.6121
$0.77
52-Wochen-Spanne:
$0.6121
$13.50
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Firmenname
Bioaffinity Technologies Inc
Sektor
Branche
Telefon
210-698-5334
Adresse
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF vs TMO, DHR, IDXX, NTRA, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
0.7037 | 4.47M | 5.66M | -15.88M | -10.93M | -11.31 |
TMO
Thermo Fisher Scientific Inc
|
532.48 | 201.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.83 | 145.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
567.44 | 45.44B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
271.39 | 38.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
131.46 | 38.44B | 7.23B | 1.41B | 1.09B | 4.979 |
Bioaffinity Technologies Inc Aktie (BIAF) Neueste Nachrichten
bioAffinity Technologies Initiates New Study for Expanding CyPath Lung Tech - Medical Product Outsourcing
bioAffinity Technologies Inc Warrant 2022- on bioAffinity Financial Disclosures & SEC Filings - TradingView
BIAF stock plunges 77% in 3 months: Should you still hold or sell? - MSN
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell? - The Globe and Mail
Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar - AOL.com
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering - AOL.com
bioAffinity reports 200% jump in lung test sales year-over-year By Investing.com - Investing.com South Africa
bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues - BioSpace
bioAffinity Technologies’ CyPath Lung Test Sees Rapid Growth - TipRanks
bioAffinity Technologies Sets New Record as CyPath® Lung Sales Double with Over 200% Year-Over-Year Growth in Q2 2026 1 – Minichart - Minichart
bioAffinity reports 200% jump in lung test sales year-over-year - Investing.com
bioAffinity Technologies Q2 CyPath® Lung Sales More Than Double Year‑Over‑Year - TradingView
CyPath Lung demand surges as bioAffinity (BIAF) Q2 2026 test volume more than triples - Stock Titan
bioAffinity Technologies (BIAF) Holds Near Support as Trading Volume Remains ElevatedNaked POC - dars.gov.et
BIAF Stock Gains As CyPath Sales Surge 146% In Q1 - Stocktwits
bioAffinity Technologies Sees Record CyPath® Lung Test Sales, Expands Veteran Screening with Philips Partnership - Minichart
bioAffinity Highlights Surge in CyPath Lung Test Adoption - TipRanks
bioAffinity Technologies reports accelerated CyPath Lung sales, Philips partnership to boost veteran screening - TradingView
CyPath Lung sales surge as bioAffinity (NASDAQ: BIAF) expands pipeline - Stock Titan
bioAffinity Technologies Company Profile & Introduction - Moomoo
BIAF Q3 2025 Earnings: EPS Misses Estimates as Company Continues R&D FocusForward EPS Estimate - DonanımHaber
bioAffinity Technologies Inc (BIAF) Valuation: PE, PB & Fair Value Analysis - TradingKey
bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells - BioSpace
bioAffinity Technologies reports skin cancer siRNA preclinical results - grafa.com
bioAffinity to present skin cancer treatment research - Investing.com
bioAffinity to present skin cancer treatment research By Investing.com - Investing.com South Africa
BIOAFFINITY TECHNOLOGIES INC (BIAF) Stock Chart - ChartMill
BioAffinity Technologies Closes $3.2 Million Public Offering - Moomoo
bioAffinity Technologies Raises $3.2M in Best-Efforts Offering, Signs Purchase and Placement Pacts - TradingView
bioAffinity Technologies Inc (BIAFW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
bioAffinity Technologies (NASDAQ: BIAF) raises $3.2M in stock and pre-funded warrant sale - Stock Titan
bioAffinity Technologies Announces Closing of $3.2 Million Offering - Quantisnow
bioAffinity Technologies closes $3.2M public offering By Investing.com - Investing.com Nigeria
bioAffinity Technologies closes $3.2M public offering - Investing.com
BIOAFFINITY TECHNOLOGIES ANNOUNCES CLOSING OF $3.2 MILLION OFFERING - Moomoo
bioAffinity Technologies Inc (BIAFW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
bioAffinity Technologies Inc (BIAFW) Institutional Confidence - TradingKey
bioAffinity Technologies Inc (BIAFW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
bioAffinity Technologies Inc (BIAFW) Valuation: PE, PB & Fair Value Analysis - TradingKey
bioAffinity (NASDAQ: BIAF) to sell 1.04M shares, up to 2.96M pre-funded warrants - Stock Titan
bioAffinity Technologies Inc (BIAF) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
bioAffinity Technologies Inc (BIAF) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
bioAffinity Technologies Inc (BIAF) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
bioAffinity Technologies Inc (BIAF) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BioAffinity Technologies Prices $3.2 Million Offering; Shares Drop 13% - Moomoo
bioAffinity Technologies (BIAF) Slides Nearly 12% – Testing Key Support at $0.79Impulse Wave - newsline.com
bioAffinity Technologies Inc (BIAF) Institutional Confidence - TradingKey
bioAffinity Technologies Inc (BIAF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
bioAffinity Technologies Inc (BIAF) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Finanzdaten der Bioaffinity Technologies Inc-Aktie (BIAF)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):